Why Are Top Stocks Moving Before the Bell Today? Pre-Market Movers March 18

March 18, 2026 — The pre-market session is alive Wednesday morning with five major stocks moving sharply before the bell. Investors are positioning ahead of the open, digesting overnight earnings reports, FDA decisions, and macroeconomic data. Here's what you need to know about today's biggest pre-market movers and why stocks are moving before market open today.

What's Driving Pre-Market Stock Moves on March 18

Nvidia (NVDA): The AI chip giant is up 8.2% pre-market to $142.50 on 4.8M shares (vs. 22M average daily volume) after an overnight report indicated stronger-than-expected enterprise data center bookings for Q1 2027. Goldman Sachs initiated coverage with a $175 Buy rating, citing "accelerating AI infrastructure spending by cloud providers." This is NVDA's largest pre-market gain since January 14, 2026, when it jumped 7.9% on similar data center tailwinds.

Tesla (TSLA): The EV manufacturer is down 4.1% pre-market to $218.75 on elevated 3.2M pre-market volume after management guided FY2026 delivery growth at just 15-18% — below the 25%+ consensus expectation. CEO Elon Musk cited supply chain constraints and competition from legacy automakers entering the EV space. The stock is now testing key support at the $215 level, which held in late February during the broader market correction.

Amgen (AMGN): The pharma blue-chip is up 5.3% pre-market to $94.20 after the FDA approved its Alzheimer's disease treatment candidate ahead of the expected April 15 decision date. The accelerated approval clears the way for revenue generation by Q2 2026 and positions Amgen ahead of competing therapies from Eli Lilly and Biogen. Citi upgraded the stock to Buy with a $108 price target.

Regeneron Pharmaceuticals (REGN): The biotech firm is up 4.8% pre-market to $687.40 after reporting phase III data for its monoclonal antibody therapy showing 34% efficacy improvement over standard treatment. The data de-risks a November FDA decision and opens a potential $2.1B peak sales market opportunity.

Berkshire Hathaway (BRK.A): Trading down 2.1% pre-market to $639,800 after Warren Buffett disclosed a $18.5B stock buyback in his Q4 2025 earnings report, signaling cautious optimism about market valuations but limited deployment of its $157B cash hoard. The market is interpreting this as a neutral-to-bearish signal on near-term equity opportunities.

Pre-Market Volume and Volatility Drivers

Pre-market trading volume this morning totaled 312M shares across all exchanges by 7:45 a.m. ET — 68% higher than the 30-day average of 185M shares at this hour. This elevation reflects overnight earnings catalysts, geopolitical data releases, and futures market positioning ahead of the earnings calendar inflection point on March 25.

Volatility drivers today include Fed speakers scheduled for 10 a.m. ET (Fed Chair Powell on inflation expectations) and jobless claims data at 8:30 a.m. ET. Futures are pointing to a flat-to-slightly-lower open for the S&P 500 as growth concerns offset the NVDA-led tech rally.

Key Technical Levels to Watch at the Open

NVDA Support and Resistance: The stock faces resistance at $147 (50-day moving average) and $151 (highs from March 10). Support sits at $136 (20-day MA). The 52-week high stands at $178, printed in December 2025.

TSLA Support and Resistance: Tesla's critical support level is $215 (tested in early March). Resistance is at $228 (50-day MA) and $235 (200-day MA). The stock is now 8.4% below its 52-week high of $238, printed on March 5.

AMGN Support and Resistance: Amgen shows resistance at the $98 level (50-day MA) and support at $87 (200-day MA). Volume on the approval news reached 6.2M shares pre-market — 4.1x the 30-day average of 1.5M.

Learn more about how to interpret technical levels and moving averages to inform your trading decisions.

What Analysts Say About Today's Pre-Market Movers

NVDA Consensus: 32 Buy, 6 Hold, 1 Sell. Average price target: $168 (18.2% upside from pre-market levels). The recent Goldman Sachs upgrade to $175 is the most bullish call on the Street.

TSLA Consensus: 18 Buy, 14 Hold, 8 Sell. Average price target: $242 (10.6% upside, though consensus may shift lower on today's guidance miss). Morgan Stanley maintained a $260 overweight, citing long-term EV adoption tailwinds, but noted near-term execution risk.

AMGN Consensus: 22 Buy, 8 Hold, 2 Sell. Average price target: $105 (11.4% upside). Today's FDA approval accelerates a consensus Buy bias that was already present.

REGN Consensus: 19 Buy, 7 Hold, 1 Sell. Average price target: $715 (4.1% upside). The phase III data supports the bullish case and validates the November FDA timeline.

What's Next for Pre-Market Movers Today

NVDA: Next catalyst is Q1 FY2027 earnings on May 22, 2026. Management is expected to guide Q2 revenue of $29.5B+ (up 8%+ sequentially). Data center segment is forecast to represent 88% of total revenue. The bull case assumes further AI infrastructure acceleration drives the stock to $175+ by June. The bear case targets $130 if enterprise spending softens, citing potential margin compression from competitive pricing pressure.

TSLA: The next catalyst is monthly delivery numbers for March, expected April 1, 2026. Bulls target a rally to $245 on evidence of faster demand recovery in China. Bears are eyeing the $200 support level if April deliveries disappoint, given today's guidance miss signals underlying demand pressure.

AMGN: The next catalyst is Q1 2026 earnings on April 22, with potential commercial revenue guidance for the newly approved Alzheimer's therapy. The bull case targets $110+ by June if early uptake exceeds 15% of addressable patient population. Bears cite execution risk on label expansion and pricing pressure from competing therapies.

REGN: The next major catalyst is FDA decision on November 15, 2026 (now de-risked by today's data). Commercial launch could begin Q1 2027 if approved.

Frequently Asked Questions

Why are stocks moving before the market opens today (March 18)?

Overnight earnings announcements, FDA approvals, and macro data drive pre-market moves. NVDA surged 8.2% on data center demand signals, TSLA dropped 4.1% on missed delivery guidance, and biotech stocks AMGN and REGN each gained 5%+ on separate FDA catalysts. Pre-market moves often reverse or amplify once the full session opens at 9:30 a.m. ET.

Should I trade stocks before the market opens?

Pre-market trading (4 a.m.–9:30 a.m. ET) offers lower liquidity, wider bid-ask spreads, and higher volatility than regular hours. Many brokers restrict order types and sizes. Most traders wait for the official 9:30 a.m. open to establish positions in large-cap stocks.

What is the difference between pre-market and regular trading?

Pre-market trading occurs before the 9:30 a.m. ET official market open and after the 4 p.m. ET close. Volume is typically 60-80% lower than regular session volume. Spreads are wider, making it harder to execute at predictable prices.

How can I trade pre-market stocks?

Most major brokers (Fidelity, Charles Schwab, E*TRADE) allow pre-market trading via limit orders only. Check your broker's specific hours and restrictions. Understanding volume patterns is critical for pre-market trading success.

Are pre-market moves predictive of the regular session open?

Pre-market moves correlate with regular session opens roughly 65-70% of the time, depending on market sentiment and liquidity. Large pre-market gaps sometimes fade as retail traders enter at the open or macro data reverses the narrative.

Stay updated on today's market news and track the full list of NVDA stock movements throughout the session.